Search Results
Results 51 - 100 of 1731
1 2 3 4 5 6 7 8 9 10 >
Grundeken Maik J - - 2013
Coronary bifurcation lesions account for approximately 15% of all percutaneous coronary interventions (PCI) performed. Although clinical outcomes after PCI have been improved considerably, PCI of bifurcation lesions remains to be associated with adverse clinical events, when compared with non-bifurcation PCI. Therefore, several dedicated bifurcation devices have been developed to improve ...
Smulders Martijn W - - 2013
Although high-sensitivity cardiac troponin (hs-cTn) substantially improves the early detection of myocardial injury, it lacks specificity for acute myocardial infarction (MI). In suspected non-ST-elevation MI, invasive coronary angiography (ICA) remains necessary to distinguish between acute MI and noncoronary myocardial disease (eg, myocarditis), unnecessarily subjecting the latter to ICA and associated ...
Moussa Issam D ID Mayo Clinic, Jacksonville, Florida. Electronic address: - - 2013
Numerous definitions have been proposed for the diagnosis of myocardial infarction (MI) after coronary revascularization. The universal definition for MI designates post procedural biomarker thresholds for defining percutaneous coronary intervention (PCI)-related MI (type 4a) and coronary artery bypass grafting (CABG)-related MI (type 5), which are of uncertain prognostic importance. In ...
Moon James C - - 2013
Rapid innovations in cardiovascular magnetic resonance (CMR) now permit the routine acquisition of quantitative measures of myocardial and blood T1 which are key tissue characteristics. These capabilities introduce a new frontier in cardiology, enabling the practitioner/investigator to quantify biologically important myocardial properties that otherwise can be difficult to ascertain clinically. ...
Gutiérrez-Chico J L - - 2013
Percutaneous coronary interventions (PCI) have gained widespread acceptation among cardiologists and among the general population for a variety of clinical indications, comprising from stable angina to ST-elevation acute myocardial infarction, due to the undisputed clinical benefit they provide and to their large availability and accessibility. Nonetheless PCI in the left ...
Vervloet M G - - 2013
Secondary hyperparathyroidism is an almost inevitable complication of advanced kidney failure. The introduction of the calcimimetic cinacalcet for the treatment of secondary hyperparathyroidism in patients on dialysis was based on its ability to reduce elevated levels of parathyroid hormone (PTH). Subsequent clinical studies confirmed the beneficial effects of cinacalcet on ...
Phillips Lawrence M - - 2013
There is a preponderance of evidence that, in the setting of an acute coronary syndrome, an invasive approach using coronary revascularization has a morbidity and mortality benefit. However, recent stable ischemic heart disease (SIHD) randomized clinical trials testing whether the addition of coronary revascularization to guideline-directed medical therapy (GDMT) reduces ...
Thompson Peter L - - 2013
Rupture or erosion of an unstable atherosclerotic plaque is the typical pathology and usual cause of acute coronary syndromes. Despite detailed understanding of the processes of lipid accumulation, thinning of the fibrous cap, and inflammation leading to plaque instability, there are no strategies in clinical use that uniquely target the ...
Szady Anita D AD Division of Cardiovascular Medicine, University of Florida College of Medicine, 1600 S.W. Archer Rd, Gainesville, FL, USA. - - 2013
The purpose of stem cell therapy for myocardial infarction is to improve clinical outcomes, and detailed information on clinical outcomes is critical to appropriate planning of phase III trials. We have examined data from select phase II trials using autologous bone-marrow-derived stem cells in patients with acute myocardial infarction. We ...
Moussa Issam D - - 2013
Numerous definitions have been proposed for the diagnosis of myocardial infarction (MI) after coronary revascularization. The Universal Definition for MI designates post procedural biomarker thresholds for defining percutaneous coronary intervention (PCI)-related MI (type 4a) and coronary artery bypass grafting (CABG)-related MI (type 5) which are of uncertain prognostic importance. In ...
Yadav Mayank - - 2013
The introduction of the SYNTAX score (SS) has prompted a renewed interest for angiographic risk stratification in patients undergoing percutaneous coronary intervention (PCI). The SS is based on qualitative and quantitative characterization of coronary artery disease (CAD) by including 11 angiographic variables that take into consideration lesion location and characteristics. ...
Arsenault Marie - - 2013
-Aortic valve regurgitation (AR) is a volume overload disease causing severe eccentric left ventricular hypertrophy and eventually heart failure. There is currently no approved drug to treat patients with AR. Many vasodilators including angiotensin converting enzyme inhibitors have been evaluated in clinical trials but while some results were promising, others ...
Osnabrugge Ruben Lj - - 2013
The majority (70%) of coronary revascularizations concern patients with multivessel disease (MVD). Treatment options include medical therapy, percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG). CABG surgery has been shown to improve survival compared with medical therapy. PCI relieves angina compared with medical therapy and is equivalent to ...
Zannad Faiez - - 2013
Endpoint selection is a critically important step in clinical trial design. It poses major challenges for investigators, regulators, and study sponsors, and it also has important clinical and practical implications for physicians and patients. Clinical outcomes of interest in heart failure trials include all-cause mortality, cause-specific mortality, relevant non-fatal morbidity ...
Hofmann Ulrich U Department of Internal Medicine I, University Hospital Würzburg, Oberdürrbacher Straße 6, 97080, Würzburg, Germany. - - 2013
The prevalence of chronic heart failure is still increasing making it a major health issue in the 21st century. Tremendous evidence has emerged over the past decades that heart failure is associated with a wide array of mechanisms subsumed under the term "inflammation". Based on the great success of immuno-suppressive ...
Bennett Mosi K - - 2013
BACKGROUND: -Endomyocardial biopsy (EMB) is often considered when the etiology of heart failure cannot be determined by non-invasive testing. Uncertainty remains about the diagnostic and clinical utility of EMB in various clinical scenarios. METHODS AND RESULTS: -We examined the characteristics of a cohort of patients with unexplained heart failure who ...
Lee Sangjin - - 2013
The development of ventricular assist devices (VADs) over the past 5 decades as therapy for advanced heart failure (HF) has been extraordinary. Since the original VAD design by Michael DeBakey in the early 1960s, numerous devices for mechanical circulatory support have been engineered, assessed in preclinical studies, applied to human ...
Prinz Christian - - 2013
BACKGROUND: Until now, there is no consensus regarding the definition of a clinical response to cardiac resynchronization therapy (CRT) in patients with chronic heart failure (CHF) and systolic left ventricular (LV) dysfunction. The aim of this study was to evaluate if echocardiography is predictive for an objective improvement in exercise ...
Tojo Hideaki - - 2013
Human chymase, an angiotensin II-forming chymotrypsin-like serine proteinase, posses various biological actions mediating through local angiotensin II formation in the tissue level of many cardiovascular organs. Our previous experimental data have shown that chymase inhibitor increased a survival rate of the hamster post-myocardial infarction model with concomitant improvements of the ...
Woudstra Pier - - 2013
Procedure-related myocardial infarction (pMI) is directly associated with a coronary revascularization procedure, such as percutaneous coronary intervention (PCI) or CABG surgery. In contrast to spontaneous myocardial infarction (MI), the prognostic relevance of pMI is the subject of ongoing debate. Data from retrospective analyses of large, randomized clinical trials, and large, ...
Costa Marco A - - 2013
Left ventricle (LV) remodeling after anterior wall myocardial infarction leads to increased LV volumes, myocardial stress, and, ultimately, heart failure (HF). Patients have high morbidity and mortality risk, and treatment remains limited. Percutaneous ventricular restoration (PVR) therapy using the Parachute device, a fluoropolymer membrane stretched over a nitinol conical frame, ...
Shah Benoy Nalin - - 2013
A very large body of evidence-predominantly retrospective-suggests that revascularization is superior to optimal medical therapy in patients with a significant amount of 'hibernating' myocardium. Contemporary cardiological practice has embraced this standard of practice, as many centres worldwide place great emphasis upon the results of viability testing by non-invasive imaging techniques ...
Biswas Santanu - - 2013
The evaluation of ventricular function is a core component of 2-dimensional echocardiography (2DE). Given the known limitations of 2DE, a more accurate assessment of ventricular function has long been desired. Three-dimensional echocardiography (3DE) holds promise to fulfill this role while maintaining the same benefits of low cost, portability, and efficiency ...
Rubanyi Gabor M GM Cardium Therapeutics, Inc., San Diego, California 92130, USA. - - 2013
Stimulation of collateral vessel development in the heart by angiogenic growth factor therapy has been tested in animals and humans for almost two decades. Discordance between the outcome of preclinical studies and clinical trials pointed to the difficulties of translation from animal models to patients. Lessons learned in this process ...
Mrdovic Igor - - 2013
OBJECTIVES: The present trial aims at examining whether antiplatelet regimen modification, guided by assessment of the on-treatment platelet reactivity, might result with clinical benefit in moderate to high-risk patients with ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI). BACKGROUND: High platelet reactivity has been associated with an increased ...
Reddy Pramod - - 2013
ABSTRACT: Left ventricular failure (LVF) is a clinical syndrome caused by abnormal systolic or diastolic function failing to meet the metabolic requirements of the body. It is important to diagnose and manage LVF in the earliest stages to prevent mortality and morbidity. This article extensively reviews the diagnostic, therapeutic, and ...
Menon Venu V Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, USA. - - 2013
We hypothesized that the insensitivity of the electrocardiogram in identifying acute circumflex occlusion would result in differences in the distribution of the infarct-related artery (IRA) between patients with non-ST-segment elevation myocardial infarction (NSTEMI) and STEMI enrolled in the Occluded Artery Trial. We also sought to evaluate the effect of percutaneous ...
Hausenloy Derek J - - 2013
Coronary heart disease (CHD) is the leading cause of death and disability worldwide. Despite current therapy, the morbidity and mortality for patients with CHD remains significant. The most significant manifestations of CHD arise from acute myocardial ischemia-reperfusion injury (IRI) in terms of cardiomyocyte death and its long-term consequences. As such, ...
Lanza Gaetano A - - 2013
A growing amount of data is increasingly showing the relevance of coronary microvascular dysfunction (CMVD) in several clinical contexts. This article reviews techniques and clinical investigations of the main noninvasive and invasive methods proposed to study coronary microcirculation and to identify CMVD in the presence of normal coronary arteries, also ...
Talan Mark I - - 2013
Extensive research during the last decade demonstrated that a single systemic administration of -erythropoietin (EPO) lead to significant attenuation of myocardial infarction (MI) induced in animals, mostly small rodents, either by a myocardial ischemia followed by reperfusion or by a permanent ligation of a coronary artery. Both methods are critically ...
De Torres-Alba Fernando - - 2013
Coronary artery disease (CAD) and obstructive sleep apnea (OSA) are both complex and significant clinical problems. The pathophysiological mechanisms that link OSA with CAD are complex and can influence the broad spectrum of conditions caused by CAD, from subclinical atherosclerosis to myocardial infarction. OSA remains a significant clinical problem among ...
de Vries Arjen E - - 2013
Although telemonitoring is increasingly used in heart failure care, data on expectations, experiences, and organizational implications concerning telemonitoring are rarely addressed, and the optimal profile of patients who can benefit from telemonitoring has yet to be defined. To assess the actual status of use of telemonitoring and to describe the ...
Smith Rachel Ruckdeschel - - 2013
Cardiosphere-derived cells (CDCs) are under clinical development and are currently being tested in a clinical trial enrolling patients who have undergone a myocardial infarction. CDCs are presently administered via infusion into the infarct-related artery and have been shown in early clinical trials to be effective agents of myocardial regeneration. This ...
Draman M S MS Department of Endocrinology Royal College of Surgeons in Ireland, Connolly Hospital, Blanchardstown Dublin - - 2013
Silent myocardial ischaemia (SMI), defined as objective evidence of myocardial ischaemia in the absence of symptoms, has important clinical implications for the patient with coronary artery disease. We present a dramatic case of SMI in a diabetes patient who attended annual review clinic with ST elevation myocardial infarction. His troponin ...
Pride Yuri B - - 2012
Patients with myocardial infarction (MI) generally present with chest pain or pressure at rest or minimal exertion and have associated electrocardiographic changes and/or elevation of the biomarkers of myocardial necrosis. A subset of patients, however, experience little chest discomfort or do not present to medical attention despite experiencing symptoms. Unrecognized ...
Bakal Jeffrey A - - 2012
AimsThe selection of optimal endpoints for cardiovascular clinical trials continues to be challenging. We examined an alternative interpretation of a series of trials when the individual event severity is considered.Methods and resultsWe analysed three contemporary myocardial infarction (MI) trials of early percutaneous coronary intervention after fibrinolysis, using a weighted composite ...
Schmidt Michael R - - 2012
Early and successful restoration of myocardial reperfusion following an ischemic event is the most effective strategy to reduce final infarct size and improve clinical outcome. However, revascularization per se may induce further myocardial damage by myocardial ischemia-reperfusion injury and worsen clinical outcome. Therefore, new therapeutic strategies are required to protect ...
Park Seung-Jung - - 2012
PURPOSE OF REVIEW: To address the clinical benefit of fractional flow reserve (FFR) measurement in stable coronary artery disease (CAD) patients. RECENT FINDINGS: The efficacy of revascularization in patients with stable CAD has been debatable. However, there has been consensus that revascularization for ischemic-producing lesions may improve clinical outcomes. FFR ...
Vranckx Pascal - - 2012
BACKGROUND: Globalisation in coronary stent research calls for harmonization of clinical endpoint definitions and event adjudication. Little has been published about the various processes used for event adjudication or their impact on outcome reporting. METHODS AND RESULTS: We performed a validation of the clinical event committee (CEC) adjudication process on ...
Boyle Kimberly L - - 2012
To review the pharmacology, research developments, and clinical uses of pimobendan Original research articles and clinical studies from 1984 to August 2011. Pimobendan is approved for use in dogs for the treatment of congestive heart failure (CHF) secondary to chronic valvular heart disease (CVHD) and dilated cardiomyopathy (DCM). Expert-based veterinary ...
Jacquemart Caroline - - 2012
We report the case of a child with catecholaminergic polymorphic ventricular tachycardia, who had inappropriate electric shocks by an implantable cardioverter defibrillator and from recurrence of arrhythmias despite an appropriate β-blocking treatment. An additional treatment by flecainide completely suppressed inappropriate shocks due to sinusal tachycardia and ventricular tachyarrhythmias. We briefly ...
Hasdemir Can - - 2012
We present a case of 38-year-old woman with stress cardiomyopathy presenting to the emergency department with a 1-week history of recurrent syncope due to sustained polymorphic ventricular tachycardia. (PACE 2012;00:e1-e3).
Kazemi Ahmad - - 2012
The impact of platelet collagen receptor polymorphisms in the pathogenesis of myocardial infarction at young age remains unknown. To determine whether either of the two platelet collagen receptor polymorphisms (GP VI T13254C and GP Ia C807T) was associated with premature acute myocardial infarction. One hundred patients with premature acute myocardial ...
Wang L P - - 2012
Activation of the peroxisome proliferator-activated receptor g (PPARg) improves insulin sensitivity and inhibits atherosclerosis. Whether PPARg2 Pro12Ala polymorphism affects myocardial infarction is not clearly understood. We investigated a possible association of PPARg2 Pro12Ala polymorphism with obesity and myocardial infarction in Han Chinese in Hohhot, Inner Mongolia, China. We included 121 ...
Nascimento Bruno Costa do - - 2012
BACKGROUND: The sympathetic nervous system is of great importance in the pathogenesis of atrial fibrillation in systolic heart failure. The identification of polymorphisms in the beta1-adrenergic receptor gene (ADBR1) represents an important step in understanding this pathogenesis. OBJECTIVE: This study assessed the association between the two functional polymorphisms of the ...
Huemer Martin - - 2012
We present a patient with polymorphic ventricular tachycardia and subsequent ventricular fibrillation with acquired long QT syndrome secondary to herpes encephalitis.
Chang Wei-To - - 2012
Acute myocardial infarction is a highly prevalent cardiovascular disease in Taiwan. Among several etiological risk factors, obesity and inflammation are strongly associated with the frequency of hypertension, cardiovascular disease, diabetes, and myocardial infarction. To discriminate obesity- and inflammation-related genes and the onset of acute myocardial infarction (AMI), a case-control study ...
Wu Katherine C - - 2012
Microvascular obstruction (MO) or no-reflow phenomenon is an established complication of coronary reperfusion therapy for acute myocardial infarction. It is increasingly recognized as a poor prognostic indicator and marker of subsequent adverse LV remodeling. Although MO can be assessed using various imaging modalities including electrocardiography, myocardial contrast echocardiography, nuclear scintigraphy, ...
Wang Xiao X Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, - - 2011
The coronary slow flow phenomenon (CSFP) is an important, angiographic entity characterized by delayed progression of the injected contrast medium through the coronary tree. It is a frequent finding, typically observed in patients presenting with acute coronary syndromes. Although it is well known to interventional cardiologists for approximately four decades, ...
De Mattia Luca - - 2011
A 54-year-old patient with episodes of paroxysmal supraventricular tachycardia developed non-sustained polymorphic ventricular tachycardia during Valsalva manoeuvre.
1 2 3 4 5 6 7 8 9 10 >